Levilimab vs Sarilumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: IL-6 receptor · full Rheumatoid Arthritis pipeline

Levilimab · Ilsira

Marketed by Biocad

Phase 3 in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT04227366 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 154 patients that measured ACR20 response, a validated rheumatoid arthritis disease-activity measure, at week 12. Levilimab combined with methotrexate produced a much higher response rate than placebo combined with methotrexate (68.6% vs 38.5%).

Reported efficacy

ACR 20 response (Week 12); Low disease activity (Week 24): ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate). (met)

Result source: NCT04227366

Sarilumab

Marketed by Sanofi and partners

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT01061736 · Phase 2/3 · completed

This was a large, randomized, triple-blind, placebo-controlled trial with adequate sample size and hard clinical/functional/radiographic primary endpoints (ACR20 response, HAQ-DI, and van der Heijde-modified Total Sharp Score). In the confirmatory Part B, both sarilumab 150 mg and 200 mg every 2 weeks met all three primary endpoints with highly significant differences from placebo (p<0.0001), and Part A also showed significant ACR20 responses for several sarilumab doses. The positive, well-designed confirmatory results support strong evidence for sarilumab.

Next expected readout: March 2028 · NCT03414502 (registry estimate)

Reported efficacy

DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106) (met)

Result source: NCT02332590

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLevilimabSarilumab
ACR2068.6% vs 38.5%a+30.1 vs placebowk 12NCT0422736666.4% vs 33.4%+33 vs placebo200 mg q2w · wk 24 · n 399NCT01061736
11 other results
  • 60.9% vs 33.7% 200 mg q2w · wk 24 · n 184 · Phase 3 · primary NCT01709578
  • 58% vs 33.4% 150 mg q2w · wk 24 · n 400 · Phase 2/3 · primary NCT01061736
  • 55.8% vs 33.7% 150 mg q2w · wk 24 · n 181 · Phase 3 · primary NCT01709578
  • 65.4% vs 46.2% 200 mg q2w · wk 12 · n 52 · Phase 2/3 · primary NCT01061736
  • 57.5% vs 14.8% 200 mg · wk 24 · n 80 · Phase 3 · primary NCT02293902
  • 72% vs 46.2% 150 mg qw · wk 12 · n 50 · Phase 2/3 · primary NCT01061736
  • 66.7% vs 46.2% 150 mg q2w · wk 12 · n 51 · Phase 2/3 · primary NCT01061736
  • 67.9% vs 14.8% 150 mg · wk 24 · n 81 · Phase 3 · primary NCT02293902
  • 62% vs 46.2% 100 mg qw · wk 12 · n 50 · Phase 2/3 · primary NCT01061736
  • 49% vs 46.2% 100 mg q2w · wk 12 · n 51 · Phase 2/3 · primary NCT01061736
  • 71.7% vs 58.4% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
ACR50—Not posted · NCT0422736640.8% vs 18.2%+22.6 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
2 other results
  • 37% vs 18.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 45.7% vs 29.7% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
ACR70—Not posted · NCT0422736616.3% vs 7.2%+9.1 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
2 other results
  • 19.9% vs 7.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 23.4% vs 11.9% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
DAS28-CRP remission—Not posted · NCT0422736628.8% vs 7.2%+21.6 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
4 other results
  • 17.9% vs 3.9% 200 mg q2w · wk 12 · n 184 · Phase 3 · secondary NCT01709578
  • 24.9% vs 7.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 17.1% vs 3.9% 150 mg q2w · wk 12 · n 181 · Phase 3 · secondary NCT01709578
  • 34.2% vs 13.5% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
HAQ-DI, change—Not posted · NCT04227366-0.5 vs -0.3−0.2 vs placebo200 mg q2w · wk 12 · n 171NCT01709578
4 other results
  • -0.5 vs -0.3 150 mg q2w · wk 12 · n 165 · Phase 3 · primary NCT01709578
  • -0.6 vs -0.3 200 mg q2w · wk 24 · n 136 · Phase 3 · secondary NCT01709578
  • -0.5 vs -0.3 150 mg q2w · wk 24 · n 127 · Phase 3 · secondary NCT01709578
  • -0.6 vs -0.4 200 mg · wk 24 · n 165 · Phase 3 · secondary NCT02332590
Modified Sharp score, change—Not posted · NCT04227366—Trial running · NCT03414502

ACR20

Levilimab
68.6% vs 38.5%a+30.1 vs placebowk 12NCT04227366
Sarilumab
66.4% vs 33.4%+33 vs placebo200 mg q2w · wk 24 · n 399NCT01061736
11 other results
  • 60.9% vs 33.7% 200 mg q2w · wk 24 · n 184 · Phase 3 · primary NCT01709578
  • 58% vs 33.4% 150 mg q2w · wk 24 · n 400 · Phase 2/3 · primary NCT01061736
  • 55.8% vs 33.7% 150 mg q2w · wk 24 · n 181 · Phase 3 · primary NCT01709578
  • 65.4% vs 46.2% 200 mg q2w · wk 12 · n 52 · Phase 2/3 · primary NCT01061736
  • 57.5% vs 14.8% 200 mg · wk 24 · n 80 · Phase 3 · primary NCT02293902
  • 72% vs 46.2% 150 mg qw · wk 12 · n 50 · Phase 2/3 · primary NCT01061736
  • 66.7% vs 46.2% 150 mg q2w · wk 12 · n 51 · Phase 2/3 · primary NCT01061736
  • 67.9% vs 14.8% 150 mg · wk 24 · n 81 · Phase 3 · primary NCT02293902
  • 62% vs 46.2% 100 mg qw · wk 12 · n 50 · Phase 2/3 · primary NCT01061736
  • 49% vs 46.2% 100 mg q2w · wk 12 · n 51 · Phase 2/3 · primary NCT01061736
  • 71.7% vs 58.4% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590

ACR50

Levilimab
—Not posted · NCT04227366
Sarilumab
40.8% vs 18.2%+22.6 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
2 other results
  • 37% vs 18.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 45.7% vs 29.7% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590

ACR70

Levilimab
—Not posted · NCT04227366
Sarilumab
16.3% vs 7.2%+9.1 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
2 other results
  • 19.9% vs 7.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 23.4% vs 11.9% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590

DAS28-CRP remission

Levilimab
—Not posted · NCT04227366
Sarilumab
28.8% vs 7.2%+21.6 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
4 other results
  • 17.9% vs 3.9% 200 mg q2w · wk 12 · n 184 · Phase 3 · secondary NCT01709578
  • 24.9% vs 7.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 17.1% vs 3.9% 150 mg q2w · wk 12 · n 181 · Phase 3 · secondary NCT01709578
  • 34.2% vs 13.5% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590

HAQ-DI, change

Levilimab
—Not posted · NCT04227366
Sarilumab
-0.5 vs -0.3−0.2 vs placebo200 mg q2w · wk 12 · n 171NCT01709578
4 other results
  • -0.5 vs -0.3 150 mg q2w · wk 12 · n 165 · Phase 3 · primary NCT01709578
  • -0.6 vs -0.3 200 mg q2w · wk 24 · n 136 · Phase 3 · secondary NCT01709578
  • -0.5 vs -0.3 150 mg q2w · wk 24 · n 127 · Phase 3 · secondary NCT01709578
  • -0.6 vs -0.4 200 mg · wk 24 · n 165 · Phase 3 · secondary NCT02332590

Modified Sharp score, change

Levilimab
—Not posted · NCT04227366
Sarilumab
—Trial running · NCT03414502
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Levilimab: 0 of 4 rows · Sarilumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLevilimabSarilumab
Dropout rate—
13.5%200 mg q2wa
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
show 35 more results
—200 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
5.9%150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
8%150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
11.8%100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
26%100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
49.7%Sarilumab + Disease Modifying Anti
NCT01146652 · Phase 3 · combination
40.5%Sarilumab Monotherapy
NCT01146652 · Phase 3 · monotherapy
—200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
10.3%200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
27.7%200 mg q2w
NCT01709578 · Phase 3
30.9%150 mg q2w
NCT01709578 · Phase 3
22.6%
NCT03449758 · Phase 4 · registry result, not featured evidence
—200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
—150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
40%200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
13.3%150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
12.5%200 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
8.6%150 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
—Sarilumab Rescue
NCT02293902 · Phase 3 · registry result, not featured evidence
13.5%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
3.6%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
7.1%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
5.7%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
13.4%200 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
—200mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
10.8%150 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
—150mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
23.5%200 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
18.4%150 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs—
7.7%200 mg q2wa
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
show 35 more results
—200 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
3.9%150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
2%150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
5.9%100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
26%100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
26.5%Sarilumab + Disease Modifying Anti
NCT01146652 · Phase 3 · combination
13.5%Sarilumab Monotherapy
NCT01146652 · Phase 3 · monotherapy
—200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
6%200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
9.2%200 mg q2w
NCT01709578 · Phase 3
9.9%150 mg q2w
NCT01709578 · Phase 3
10.7%
NCT03449758 · Phase 4 · registry result, not featured evidence
—200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
—150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
33.3%200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
13.3%150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
10%200 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
7.4%150 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
—Sarilumab Rescue
NCT02293902 · Phase 3 · registry result, not featured evidence
11.5%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
1.8%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
5.4%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
3.8%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
10.4%200 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
—200mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
7.7%150 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
—150mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
17.6%200 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
16.3%150 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
Serious AEs—
0%200 mg q2wa
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
show 35 more results
12.5%200 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
0%150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
0%150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
9.5%150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
7.7%150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
5.9%100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
6%100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
0%100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
6.9%100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
32.3%Sarilumab + Disease Modifying Anti
NCT01146652 · Phase 3 · combination
24.3%Sarilumab Monotherapy
NCT01146652 · Phase 3 · monotherapy
4.9%200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
17.5%200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
5.4%200 mg q2w
NCT01709578 · Phase 3
3.3%150 mg q2w
NCT01709578 · Phase 3
11.9%
NCT03449758 · Phase 4 · registry result, not featured evidence
6.5%200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
3.3%150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
20%200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
0%150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
6.3%200 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
9.9%150 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
6.9%Sarilumab Rescue
NCT02293902 · Phase 3 · registry result, not featured evidence
5.8%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
7.1%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
1.8%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
10.1%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
—200 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
3%200mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
—150 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
1.5%150mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
5.9%200 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
2%150 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs—
200 mg q2wa
neutropenia 19.6% (placebo 0%)
upper respiratory tract infection 5.9% (placebo 3.9%)
accidental overdose 3.9% (placebo 9.8%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
show 32 more results
200 mg q2w
neutropenia 14.9% (placebo 0%)
upper respiratory tract infection 9.5% (placebo 3.9%)
alanine aminotransferase increased 8.1% (placebo 0%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
150 mg q2w
accidental overdose 5.8% (placebo 9.8%)
alanine aminotransferase increased 5.8% (placebo 0%)
nasopharyngitis 3.8% (placebo 5.9%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
150 mg qw
neutropenia 10% (placebo 0%)
accidental overdose 6% (placebo 9.8%)
rheumatoid arthritis 6% (placebo 2%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
150 mg q2w
neutropenia 9.7% (placebo 0%)
alanine aminotransferase increased 8.4% (placebo 0%)
upper respiratory tract infection 8.4% (placebo 3.9%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
150 mg qw
injection site erythema 11.5% (placebo 0%)
hypertension 7.7% (placebo 2%)
neutropenia 7.7% (placebo 0%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
100 mg q2w
hypertension 3.9% (placebo 2%)
nasopharyngitis 3.9% (placebo 5.9%)
accidental overdose 2% (placebo 9.8%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
100 mg qw
neutropenia 12% (placebo 0%)
urinary tract infection 6% (placebo 2%)
accidental overdose 4% (placebo 9.8%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
100 mg q2w
accidental overdose 10.3% (placebo 9.8%)
hypertension 6.9% (placebo 2%)
neutropenia 3.4% (placebo 0%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
100 mg qw
accidental overdose 6.9% (placebo 9.8%)
rheumatoid arthritis 6.9% (placebo 2%)
hypertension 3.4% (placebo 2%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
neutropenia 18.2%
accidental overdose 17.3%
upper respiratory tract infection 15.9%
NCT01146652 · Phase 3 · combination
accidental overdose 18%
neutropenia 16.2%
rheumatoid arthritis 14.4%
NCT01146652 · Phase 3 · monotherapy
200 mg
neutropenia 13.6%
injection site erythema 7.6%
bronchitis 6.5%
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
200 mg
nasopharyngitis 18.8%
neutropenia 18.4%
bronchitis 12.8%
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
200 mg q2w
neutropenia 12% (placebo 1.1%)
urinary tract infection 7.1% (placebo 6.6%)
alanine aminotransferase increased 5.4% (placebo 1.1%)
NCT01709578 · Phase 3
150 mg q2w
neutropenia 12.7% (placebo 1.1%)
hypertriglyceridaemia 6.1% (placebo 1.7%)
injection site erythema 6.1% (placebo 0%)
NCT01709578 · Phase 3
neutropenia 19%
bronchitis 11.9%
nausea 11.9%
NCT03449758 · Phase 4 · registry result, not featured evidence
200 mg q2w
nasopharyngitis 45.2%
injection site erythema 19.4%
hepatic function abnormal 12.9%
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
150 mg q2w
nasopharyngitis 43.3%
rheumatoid arthritis 13.3%
oropharyngeal pain 10%
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
200 mg q2w
nasopharyngitis 33.3%
stomatitis 26.7%
neutropenia 20%
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
150 mg q2w
neutropenia 33.3%
nasopharyngitis 26.7%
contusion 20%
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
200 mg
nasopharyngitis 28.8% (placebo 14.8%)
neutropenia 11.3% (placebo 0%)
stomatitis 10% (placebo 3.7%)
NCT02293902 · Phase 3 · registry result, not featured evidence
150 mg
nasopharyngitis 33.3% (placebo 14.8%)
neutropenia 12.3% (placebo 0%)
hepatic function abnormal 9.9% (placebo 4.9%)
NCT02293902 · Phase 3 · registry result, not featured evidence
nasopharyngitis 32.8% (placebo 14.8%)
stomatitis 12.1% (placebo 3.7%)
neutropenia 10.3% (placebo 0%)
NCT02293902 · Phase 3 · registry result, not featured evidence
200 mg
neutropenia 11.5%
alanine aminotransferase increased 9.6%
injection site erythema 7.7%
NCT02057250 · Phase 3 · registry result, not featured evidence
200 mg
injection site erythema 7.1%
injection site pruritus 7.1%
neutropenia 7.1%
NCT02057250 · Phase 3 · registry result, not featured evidence
150 mg
neutropenia 17.9%
pharyngitis 8.9%
bronchitis 7.1%
NCT02057250 · Phase 3 · registry result, not featured evidence
150 mg
neutropenia 17%
sinusitis 5.7%
injection site erythema 3.8%
NCT02057250 · Phase 3 · registry result, not featured evidence
150 mg
upper respiratory tract infection 13.3%
neutropenia 6.4%
sinusitis 6.4%
NCT02057250 · Phase 3 · registry result, not featured evidence
200mg q2w
neutropenia 16.4%
hypertension 6%
upper respiratory tract infection 6%
NCT02121210 · Phase 3 · registry result, not featured evidence
150mg q2w
neutropenia 12.3%
injection site erythema 7.7%
upper respiratory tract infection 4.6%
NCT02121210 · Phase 3 · registry result, not featured evidence
200 mg q2w
neutropenia 15.7%
injection site erythema 7.8%
accidental overdose 5.9%
NCT01768572 · Phase 3 · registry result, not featured evidence
150 mg q2w
nasopharyngitis 12.2%
neutropenia 12.2%
injection site erythema 8.2%
NCT01768572 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 23 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sarilumab

Major Clinical 14.8% (n=399) vs 3% (n=398) placebo @ 52wk200 mg q2w
responder rate · % of participants
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
show 1 more result
12.8% (n=400) vs 3% (n=398) placebo @ 52wk150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
ACR20 69.4% (n=1898) @ 0wk
responder rate · % of participants
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 35 more results
82% (n=111) @ 0wk
NCT01146652 · Phase 3 · monotherapy
77.8% (n=1898) @ 4wk
NCT01146652 · Phase 3 · combination
85.8% (n=111) @ 4wk
NCT01146652 · Phase 3 · monotherapy
80.2% (n=1898) @ 8wk
NCT01146652 · Phase 3 · combination
92.5% (n=111) @ 8wk
NCT01146652 · Phase 3 · monotherapy
80.3% (n=1898) @ 12wk
NCT01146652 · Phase 3 · combination
91.7% (n=111) @ 12wk
NCT01146652 · Phase 3 · monotherapy
82.9% (n=1898) @ 24wk
NCT01146652 · Phase 3 · combination
88.1% (n=111) @ 24wk
NCT01146652 · Phase 3 · monotherapy
82.8% (n=1898) @ 36wk
NCT01146652 · Phase 3 · combination
91.7% (n=111) @ 36wk
NCT01146652 · Phase 3 · monotherapy
82.9% (n=1898) @ 48wk
NCT01146652 · Phase 3 · combination
85% (n=111) @ 48wk
NCT01146652 · Phase 3 · monotherapy
84.6% (n=1898) @ 60wk
NCT01146652 · Phase 3 · combination
93.2% (n=111) @ 60wk
NCT01146652 · Phase 3 · monotherapy
84.4% (n=1898) @ 72wk
NCT01146652 · Phase 3 · combination
94.1% (n=111) @ 72wk
NCT01146652 · Phase 3 · monotherapy
84.5% (n=1898) @ 84wk
NCT01146652 · Phase 3 · combination
94.7% (n=111) @ 84wk
NCT01146652 · Phase 3 · monotherapy
85.2% (n=1898) @ 96wk
NCT01146652 · Phase 3 · combination
91.3% (n=111) @ 96wk
NCT01146652 · Phase 3 · monotherapy
84.9% (n=1898) @ 120wk
NCT01146652 · Phase 3 · combination
90.9% (n=111) @ 120wk
NCT01146652 · Phase 3 · monotherapy
86.4% (n=1898) @ 144wk
NCT01146652 · Phase 3 · combination
94% (n=111) @ 144wk
NCT01146652 · Phase 3 · monotherapy
86% (n=1898) @ 168wk
NCT01146652 · Phase 3 · combination
90.1% (n=111) @ 168wk
NCT01146652 · Phase 3 · monotherapy
85.7% (n=1898) @ 192wk
NCT01146652 · Phase 3 · combination
89.3% (n=111) @ 192wk
NCT01146652 · Phase 3 · monotherapy
87.1% (n=1898) @ 216wk
NCT01146652 · Phase 3 · combination
89.2% (n=111) @ 216wk
NCT01146652 · Phase 3 · monotherapy
86.4% (n=1898) @ 240wk
NCT01146652 · Phase 3 · combination
91.9% (n=111) @ 240wk
NCT01146652 · Phase 3 · monotherapy
88.5% (n=1898) @ 264wk
NCT01146652 · Phase 3 · combination
90.2% (n=111) @ 264wk
NCT01146652 · Phase 3 · monotherapy
ACR50 43.4% (n=1897) @ 0wk
responder rate · % of participants
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 35 more results
58.6% (n=111) @ 0wk
NCT01146652 · Phase 3 · monotherapy
51.3% (n=1897) @ 4wk
NCT01146652 · Phase 3 · combination
59.3% (n=111) @ 4wk
NCT01146652 · Phase 3 · monotherapy
55.1% (n=1897) @ 8wk
NCT01146652 · Phase 3 · combination
59% (n=111) @ 8wk
NCT01146652 · Phase 3 · monotherapy
58.1% (n=1897) @ 12wk
NCT01146652 · Phase 3 · combination
66.7% (n=111) @ 12wk
NCT01146652 · Phase 3 · monotherapy
60.5% (n=1897) @ 24wk
NCT01146652 · Phase 3 · combination
64.2% (n=111) @ 24wk
NCT01146652 · Phase 3 · monotherapy
62.1% (n=1897) @ 36wk
NCT01146652 · Phase 3 · combination
64.2% (n=111) @ 36wk
NCT01146652 · Phase 3 · monotherapy
62.4% (n=1897) @ 48wk
NCT01146652 · Phase 3 · combination
69.2% (n=111) @ 48wk
NCT01146652 · Phase 3 · monotherapy
63.2% (n=1897) @ 60wk
NCT01146652 · Phase 3 · combination
68.9% (n=111) @ 60wk
NCT01146652 · Phase 3 · monotherapy
64.8% (n=1897) @ 72wk
NCT01146652 · Phase 3 · combination
71.3% (n=111) @ 72wk
NCT01146652 · Phase 3 · monotherapy
63.6% (n=1897) @ 84wk
NCT01146652 · Phase 3 · combination
73.4% (n=111) @ 84wk
NCT01146652 · Phase 3 · monotherapy
65.3% (n=1897) @ 96wk
NCT01146652 · Phase 3 · combination
71.7% (n=111) @ 96wk
NCT01146652 · Phase 3 · monotherapy
65.6% (n=1897) @ 120wk
NCT01146652 · Phase 3 · combination
73.6% (n=111) @ 120wk
NCT01146652 · Phase 3 · monotherapy
65.7% (n=1897) @ 144wk
NCT01146652 · Phase 3 · combination
70.2% (n=111) @ 144wk
NCT01146652 · Phase 3 · monotherapy
66.2% (n=1897) @ 168wk
NCT01146652 · Phase 3 · combination
70% (n=111) @ 168wk
NCT01146652 · Phase 3 · monotherapy
68.4% (n=1897) @ 192wk
NCT01146652 · Phase 3 · combination
70.7% (n=111) @ 192wk
NCT01146652 · Phase 3 · monotherapy
69% (n=1897) @ 216wk
NCT01146652 · Phase 3 · combination
75.7% (n=111) @ 216wk
NCT01146652 · Phase 3 · monotherapy
68.3% (n=1897) @ 240wk
NCT01146652 · Phase 3 · combination
79.7% (n=111) @ 240wk
NCT01146652 · Phase 3 · monotherapy
69.6% (n=1897) @ 264wk
NCT01146652 · Phase 3 · combination
71.7% (n=111) @ 264wk
NCT01146652 · Phase 3 · monotherapy
ACR70 22.9% (n=1901) @ 0wk
responder rate · % of participants
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 35 more results
32.4% (n=111) @ 0wk
NCT01146652 · Phase 3 · monotherapy
27.8% (n=1901) @ 4wk
NCT01146652 · Phase 3 · combination
31.5% (n=111) @ 4wk
NCT01146652 · Phase 3 · monotherapy
32.1% (n=1901) @ 8wk
NCT01146652 · Phase 3 · combination
36.2% (n=111) @ 8wk
NCT01146652 · Phase 3 · monotherapy
34.1% (n=1901) @ 12wk
NCT01146652 · Phase 3 · combination
43% (n=111) @ 12wk
NCT01146652 · Phase 3 · monotherapy
38.7% (n=1901) @ 24wk
NCT01146652 · Phase 3 · combination
37.4% (n=111) @ 24wk
NCT01146652 · Phase 3 · monotherapy
40.2% (n=1901) @ 36wk
NCT01146652 · Phase 3 · combination
40.4% (n=111) @ 36wk
NCT01146652 · Phase 3 · monotherapy
40.6% (n=1901) @ 48wk
NCT01146652 · Phase 3 · combination
43.8% (n=111) @ 48wk
NCT01146652 · Phase 3 · monotherapy
41.6% (n=1901) @ 60wk
NCT01146652 · Phase 3 · combination
45.6% (n=111) @ 60wk
NCT01146652 · Phase 3 · monotherapy
42.1% (n=1901) @ 72wk
NCT01146652 · Phase 3 · combination
49% (n=111) @ 72wk
NCT01146652 · Phase 3 · monotherapy
41.8% (n=1901) @ 84wk
NCT01146652 · Phase 3 · combination
52.1% (n=111) @ 84wk
NCT01146652 · Phase 3 · monotherapy
43.4% (n=1901) @ 96wk
NCT01146652 · Phase 3 · combination
55.4% (n=111) @ 96wk
NCT01146652 · Phase 3 · monotherapy
42.9% (n=1901) @ 120wk
NCT01146652 · Phase 3 · combination
56.8% (n=111) @ 120wk
NCT01146652 · Phase 3 · monotherapy
44.7% (n=1901) @ 144wk
NCT01146652 · Phase 3 · combination
50% (n=111) @ 144wk
NCT01146652 · Phase 3 · monotherapy
45.6% (n=1901) @ 168wk
NCT01146652 · Phase 3 · combination
51.3% (n=111) @ 168wk
NCT01146652 · Phase 3 · monotherapy
47.9% (n=1901) @ 192wk
NCT01146652 · Phase 3 · combination
53.9% (n=111) @ 192wk
NCT01146652 · Phase 3 · monotherapy
46.8% (n=1901) @ 216wk
NCT01146652 · Phase 3 · combination
62% (n=111) @ 216wk
NCT01146652 · Phase 3 · monotherapy
47.9% (n=1901) @ 240wk
NCT01146652 · Phase 3 · combination
60.8% (n=111) @ 240wk
NCT01146652 · Phase 3 · monotherapy
48.8% (n=1901) @ 264wk
NCT01146652 · Phase 3 · combination
58.3% (n=111) @ 264wk
NCT01146652 · Phase 3 · monotherapy
DAS28 Remission 30.4% (n=1873) @ 0wk
responder rate · % of participants
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 48 more results
46.4% (n=110) @ 0wk
NCT01146652 · Phase 3 · monotherapy
39.2% (n=1873) @ 4wk
NCT01146652 · Phase 3 · combination
51.9% (n=110) @ 4wk
NCT01146652 · Phase 3 · monotherapy
44.6% (n=1873) @ 8wk
NCT01146652 · Phase 3 · combination
49.5% (n=110) @ 8wk
NCT01146652 · Phase 3 · monotherapy
47.9% (n=1873) @ 12wk
NCT01146652 · Phase 3 · combination
55% (n=110) @ 12wk
NCT01146652 · Phase 3 · monotherapy
50.6% (n=1873) @ 24wk
NCT01146652 · Phase 3 · combination
59.6% (n=110) @ 24wk
NCT01146652 · Phase 3 · monotherapy
51.7% (n=1873) @ 36wk
NCT01146652 · Phase 3 · combination
59.6% (n=110) @ 36wk
NCT01146652 · Phase 3 · monotherapy
53.7% (n=1873) @ 48wk
NCT01146652 · Phase 3 · combination
56.1% (n=110) @ 48wk
NCT01146652 · Phase 3 · monotherapy
56.5% (n=1873) @ 60wk
NCT01146652 · Phase 3 · combination
61.8% (n=110) @ 60wk
NCT01146652 · Phase 3 · monotherapy
55.8% (n=1873) @ 72wk
NCT01146652 · Phase 3 · combination
68.3% (n=110) @ 72wk
NCT01146652 · Phase 3 · monotherapy
55.8% (n=1873) @ 84wk
NCT01146652 · Phase 3 · combination
70.5% (n=110) @ 84wk
NCT01146652 · Phase 3 · monotherapy
57% (n=1873) @ 96wk
NCT01146652 · Phase 3 · combination
71.7% (n=110) @ 96wk
NCT01146652 · Phase 3 · monotherapy
59.2% (n=1873) @ 120wk
NCT01146652 · Phase 3 · combination
73.9% (n=110) @ 120wk
NCT01146652 · Phase 3 · monotherapy
59.3% (n=1873) @ 144wk
NCT01146652 · Phase 3 · combination
72.3% (n=110) @ 144wk
NCT01146652 · Phase 3 · monotherapy
59.7% (n=1873) @ 168wk
NCT01146652 · Phase 3 · combination
70.4% (n=110) @ 168wk
NCT01146652 · Phase 3 · monotherapy
62.1% (n=1873) @ 192wk
NCT01146652 · Phase 3 · combination
67.1% (n=110) @ 192wk
NCT01146652 · Phase 3 · monotherapy
63.6% (n=1873) @ 216wk
NCT01146652 · Phase 3 · combination
71.2% (n=110) @ 216wk
NCT01146652 · Phase 3 · monotherapy
61.6% (n=1873) @ 240wk
NCT01146652 · Phase 3 · combination
82.2% (n=110) @ 240wk
NCT01146652 · Phase 3 · monotherapy
64.4% (n=1873) @ 264wk
NCT01146652 · Phase 3 · combination
75.8% (n=110) @ 264wk
NCT01146652 · Phase 3 · monotherapy
68.7% (n=1873) @ 288wk
NCT01146652 · Phase 3 · combination
73.1% (n=110) @ 288wk
NCT01146652 · Phase 3 · monotherapy
69% (n=1873) @ 312wk
NCT01146652 · Phase 3 · combination
85.7% (n=110) @ 312wk
NCT01146652 · Phase 3 · monotherapy
72.2% (n=1873) @ 336wk
NCT01146652 · Phase 3 · combination
71.7% (n=1873) @ 360wk
NCT01146652 · Phase 3 · combination
71.6% (n=1873) @ 384wk
NCT01146652 · Phase 3 · combination
69.8% (n=1873) @ 408wk
NCT01146652 · Phase 3 · combination
76.4% (n=1873) @ 432wk
NCT01146652 · Phase 3 · combination
72.7% (n=1873) @ 456wk
NCT01146652 · Phase 3 · combination
76.9% (n=1873) @ 480wk
NCT01146652 · Phase 3 · combination
73.1% (n=1873) @ 504wk
NCT01146652 · Phase 3 · combination
50% (n=1873) @ 516wk
NCT01146652 · Phase 3 · combination
DAS28-CRP -2.47 score @ 52wk200 mg q2w
absolute change · score
No placebo or comparator arm
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
show 50 more results
-2.9 score @ 52wk150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
-2.5 score @ 0wk
NCT01146652 · Phase 3 · combination
-2.99 score @ 0wk
NCT01146652 · Phase 3 · monotherapy
-2.98 score @ 4wk
NCT01146652 · Phase 3 · combination
-3.18 score @ 4wk
NCT01146652 · Phase 3 · monotherapy
-3.12 score @ 8wk
NCT01146652 · Phase 3 · combination
-3.21 score @ 8wk
NCT01146652 · Phase 3 · monotherapy
-3.19 score @ 12wk
NCT01146652 · Phase 3 · combination
-3.28 score @ 12wk
NCT01146652 · Phase 3 · monotherapy
-3.28 score @ 24wk
NCT01146652 · Phase 3 · combination
-3.43 score @ 24wk
NCT01146652 · Phase 3 · monotherapy
-3.31 score @ 36wk
NCT01146652 · Phase 3 · combination
-3.35 score @ 36wk
NCT01146652 · Phase 3 · monotherapy
-3.35 score @ 48wk
NCT01146652 · Phase 3 · combination
-3.36 score @ 48wk
NCT01146652 · Phase 3 · monotherapy
-3.41 score @ 60wk
NCT01146652 · Phase 3 · combination
-3.5 score @ 60wk
NCT01146652 · Phase 3 · monotherapy
-3.41 score @ 72wk
NCT01146652 · Phase 3 · combination
-3.61 score @ 72wk
NCT01146652 · Phase 3 · monotherapy
-3.4 score @ 84wk
NCT01146652 · Phase 3 · combination
-3.7 score @ 84wk
NCT01146652 · Phase 3 · monotherapy
-3.46 score @ 96wk
NCT01146652 · Phase 3 · combination
-3.59 score @ 96wk
NCT01146652 · Phase 3 · monotherapy
-3.49 score @ 120wk
NCT01146652 · Phase 3 · combination
-3.72 score @ 120wk
NCT01146652 · Phase 3 · monotherapy
-3.51 score @ 144wk
NCT01146652 · Phase 3 · combination
-3.79 score @ 144wk
NCT01146652 · Phase 3 · monotherapy
-3.52 score @ 168wk
NCT01146652 · Phase 3 · combination
-3.66 score @ 168wk
NCT01146652 · Phase 3 · monotherapy
-3.55 score @ 192wk
NCT01146652 · Phase 3 · combination
-3.61 score @ 192wk
NCT01146652 · Phase 3 · monotherapy
-3.59 score @ 216wk
NCT01146652 · Phase 3 · combination
-3.71 score @ 216wk
NCT01146652 · Phase 3 · monotherapy
-3.57 score @ 240wk
NCT01146652 · Phase 3 · combination
-3.9 score @ 240wk
NCT01146652 · Phase 3 · monotherapy
-3.64 score @ 264wk
NCT01146652 · Phase 3 · combination
-3.92 score @ 264wk
NCT01146652 · Phase 3 · monotherapy
-3.8 score @ 288wk
NCT01146652 · Phase 3 · combination
-4.38 score @ 288wk
NCT01146652 · Phase 3 · monotherapy
-3.86 score @ 312wk
NCT01146652 · Phase 3 · combination
-5.62 score @ 312wk
NCT01146652 · Phase 3 · monotherapy
-3.86 score @ 336wk
NCT01146652 · Phase 3 · combination
-3.93 score @ 360wk
NCT01146652 · Phase 3 · combination
-3.99 score @ 384wk
NCT01146652 · Phase 3 · combination
-3.85 score @ 408wk
NCT01146652 · Phase 3 · combination
-4.11 score @ 432wk
NCT01146652 · Phase 3 · combination
-4.01 score @ 456wk
NCT01146652 · Phase 3 · combination
-3.69 score @ 480wk
NCT01146652 · Phase 3 · combination
-3.76 score @ 504wk
NCT01146652 · Phase 3 · combination
-3.76 score @ 516wk
NCT01146652 · Phase 3 · combination
HAQ-DI -0.34 score @ 52wk200 mg q2w
absolute change · score
No placebo or comparator arm
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
show 40 more results
-0.52 score @ 52wk150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
-0.56 score @ 0wk
NCT01146652 · Phase 3 · combination
-0.58 score @ 0wk
NCT01146652 · Phase 3 · monotherapy
-0.59 score @ 4wk
NCT01146652 · Phase 3 · combination
-0.57 score @ 4wk
NCT01146652 · Phase 3 · monotherapy
-0.63 score @ 8wk
NCT01146652 · Phase 3 · combination
-0.63 score @ 8wk
NCT01146652 · Phase 3 · monotherapy
-0.65 score @ 12wk
NCT01146652 · Phase 3 · combination
-0.65 score @ 12wk
NCT01146652 · Phase 3 · monotherapy
-0.69 score @ 24wk
NCT01146652 · Phase 3 · combination
-0.63 score @ 24wk
NCT01146652 · Phase 3 · monotherapy
-0.7 score @ 36wk
NCT01146652 · Phase 3 · combination
-0.67 score @ 36wk
NCT01146652 · Phase 3 · monotherapy
-0.7 score @ 48wk
NCT01146652 · Phase 3 · combination
-0.63 score @ 48wk
NCT01146652 · Phase 3 · monotherapy
-0.7 score @ 60wk
NCT01146652 · Phase 3 · combination
-0.67 score @ 60wk
NCT01146652 · Phase 3 · monotherapy
-0.71 score @ 72wk
NCT01146652 · Phase 3 · combination
-0.67 score @ 72wk
NCT01146652 · Phase 3 · monotherapy
-0.71 score @ 84wk
NCT01146652 · Phase 3 · combination
-0.68 score @ 84wk
NCT01146652 · Phase 3 · monotherapy
-0.72 score @ 96wk
NCT01146652 · Phase 3 · combination
-0.69 score @ 96wk
NCT01146652 · Phase 3 · monotherapy
-0.74 score @ 120wk
NCT01146652 · Phase 3 · combination
-0.67 score @ 120wk
NCT01146652 · Phase 3 · monotherapy
-0.73 score @ 144wk
NCT01146652 · Phase 3 · combination
-0.64 score @ 144wk
NCT01146652 · Phase 3 · monotherapy
-0.74 score @ 168wk
NCT01146652 · Phase 3 · combination
-0.61 score @ 168wk
NCT01146652 · Phase 3 · monotherapy
-0.74 score @ 192wk
NCT01146652 · Phase 3 · combination
-0.65 score @ 192wk
NCT01146652 · Phase 3 · monotherapy
-0.75 score @ 216wk
NCT01146652 · Phase 3 · combination
-0.62 score @ 216wk
NCT01146652 · Phase 3 · monotherapy
-0.74 score @ 240wk
NCT01146652 · Phase 3 · combination
-0.61 score @ 240wk
NCT01146652 · Phase 3 · monotherapy
-0.76 score @ 264wk
NCT01146652 · Phase 3 · combination
-0.54 score @ 264wk
NCT01146652 · Phase 3 · monotherapy
-0.2 score @ 4wk
NCT03449758 · Phase 4 · registry result, not featured evidence
-0.4 score @ 12wk
NCT03449758 · Phase 4 · registry result, not featured evidence
-0.5 score @ 24wk
NCT03449758 · Phase 4 · registry result, not featured evidence
Modified Sharp 1.05 score @ 0wk
absolute change · score
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 6 more results
1.34 score @ 48wk
NCT01146652 · Phase 3 · combination
1.6 score @ 48wk
NCT01146652 · Phase 3 · combination
2.14 score @ 96wk
NCT01146652 · Phase 3 · combination
1.83 score @ 96wk
NCT01146652 · Phase 3 · combination
2.24 score @ 144wk
NCT01146652 · Phase 3 · combination
2.83 score @ 192wk
NCT01146652 · Phase 3 · combination
mTSS no Progression 51.9% (n=889) @ 0wk
responder rate · % of participants
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 6 more results
51.2% (n=889) @ 48wk
NCT01146652 · Phase 3 · combination
46.6% (n=796) @ 48wk
NCT01146652 · Phase 3 · combination
44.2% (n=796) @ 96wk
NCT01146652 · Phase 3 · combination
48.6% (n=732) @ 96wk
NCT01146652 · Phase 3 · combination
46% (n=732) @ 144wk
NCT01146652 · Phase 3 · combination
41.8% (n=732) @ 192wk
NCT01146652 · Phase 3 · combination
TJC -16.67 joints @ 0wk
absolute change · joints
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 48 more results
-19.86 joints @ 0wk
NCT01146652 · Phase 3 · monotherapy
-18.97 joints @ 4wk
NCT01146652 · Phase 3 · combination
-20.13 joints @ 4wk
NCT01146652 · Phase 3 · monotherapy
-19.72 joints @ 8wk
NCT01146652 · Phase 3 · combination
-20.09 joints @ 8wk
NCT01146652 · Phase 3 · monotherapy
-20.2 joints @ 12wk
NCT01146652 · Phase 3 · combination
-20.05 joints @ 12wk
NCT01146652 · Phase 3 · monotherapy
-20.67 joints @ 24wk
NCT01146652 · Phase 3 · combination
-21.19 joints @ 24wk
NCT01146652 · Phase 3 · monotherapy
-20.68 joints @ 36wk
NCT01146652 · Phase 3 · combination
-20.6 joints @ 36wk
NCT01146652 · Phase 3 · monotherapy
-20.95 joints @ 48wk
NCT01146652 · Phase 3 · combination
-20.27 joints @ 48wk
NCT01146652 · Phase 3 · monotherapy
-21.29 joints @ 60wk
NCT01146652 · Phase 3 · combination
-20.95 joints @ 60wk
NCT01146652 · Phase 3 · monotherapy
-21.41 joints @ 72wk
NCT01146652 · Phase 3 · combination
-21.67 joints @ 72wk
NCT01146652 · Phase 3 · monotherapy
-21.53 joints @ 84wk
NCT01146652 · Phase 3 · combination
-21.36 joints @ 84wk
NCT01146652 · Phase 3 · monotherapy
-21.65 joints @ 96wk
NCT01146652 · Phase 3 · combination
-20.89 joints @ 96wk
NCT01146652 · Phase 3 · monotherapy
-21.92 joints @ 120wk
NCT01146652 · Phase 3 · combination
-20.18 joints @ 120wk
NCT01146652 · Phase 3 · monotherapy
-22.13 joints @ 144wk
NCT01146652 · Phase 3 · combination
-22.52 joints @ 144wk
NCT01146652 · Phase 3 · monotherapy
-22.35 joints @ 168wk
NCT01146652 · Phase 3 · combination
-22.42 joints @ 168wk
NCT01146652 · Phase 3 · monotherapy
-22.62 joints @ 192wk
NCT01146652 · Phase 3 · combination
-21.83 joints @ 192wk
NCT01146652 · Phase 3 · monotherapy
-22.69 joints @ 216wk
NCT01146652 · Phase 3 · combination
-22.33 joints @ 216wk
NCT01146652 · Phase 3 · monotherapy
-22.89 joints @ 240wk
NCT01146652 · Phase 3 · combination
-23.07 joints @ 240wk
NCT01146652 · Phase 3 · monotherapy
-23.09 joints @ 264wk
NCT01146652 · Phase 3 · combination
-23.66 joints @ 264wk
NCT01146652 · Phase 3 · monotherapy
-22.59 joints @ 288wk
NCT01146652 · Phase 3 · combination
-28.95 joints @ 288wk
NCT01146652 · Phase 3 · monotherapy
-23.47 joints @ 312wk
NCT01146652 · Phase 3 · combination
-43.71 joints @ 312wk
NCT01146652 · Phase 3 · monotherapy
-23.37 joints @ 336wk
NCT01146652 · Phase 3 · combination
-24.12 joints @ 360wk
NCT01146652 · Phase 3 · combination
-24.73 joints @ 384wk
NCT01146652 · Phase 3 · combination
-24.58 joints @ 408wk
NCT01146652 · Phase 3 · combination
-25.33 joints @ 432wk
NCT01146652 · Phase 3 · combination
-24.21 joints @ 456wk
NCT01146652 · Phase 3 · combination
-21.23 joints @ 480wk
NCT01146652 · Phase 3 · combination
-23.62 joints @ 504wk
NCT01146652 · Phase 3 · combination
-24 joints @ 516wk
NCT01146652 · Phase 3 · combination
Swollen Joint Count -11.36 joints @ 0wk
absolute change · joints
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 51 more results
-14.06 joints @ 0wk
NCT01146652 · Phase 3 · monotherapy
-12.81 joints @ 4wk
NCT01146652 · Phase 3 · combination
-14.55 joints @ 4wk
NCT01146652 · Phase 3 · monotherapy
-13.43 joints @ 8wk
NCT01146652 · Phase 3 · combination
-14.6 joints @ 8wk
NCT01146652 · Phase 3 · monotherapy
-13.77 joints @ 12wk
NCT01146652 · Phase 3 · combination
-14.58 joints @ 12wk
NCT01146652 · Phase 3 · monotherapy
-14.28 joints @ 24wk
NCT01146652 · Phase 3 · combination
-14.83 joints @ 24wk
NCT01146652 · Phase 3 · monotherapy
-14.37 joints @ 36wk
NCT01146652 · Phase 3 · combination
-14.51 joints @ 36wk
NCT01146652 · Phase 3 · monotherapy
-14.53 joints @ 48wk
NCT01146652 · Phase 3 · combination
-14.96 joints @ 48wk
NCT01146652 · Phase 3 · monotherapy
-14.75 joints @ 60wk
NCT01146652 · Phase 3 · combination
-15.54 joints @ 60wk
NCT01146652 · Phase 3 · monotherapy
-14.76 joints @ 72wk
NCT01146652 · Phase 3 · combination
-15.43 joints @ 72wk
NCT01146652 · Phase 3 · monotherapy
-14.84 joints @ 84wk
NCT01146652 · Phase 3 · combination
-15.83 joints @ 84wk
NCT01146652 · Phase 3 · monotherapy
-15.03 joints @ 96wk
NCT01146652 · Phase 3 · combination
-15.51 joints @ 96wk
NCT01146652 · Phase 3 · monotherapy
-15.09 joints @ 120wk
NCT01146652 · Phase 3 · combination
-15.77 joints @ 120wk
NCT01146652 · Phase 3 · monotherapy
-15.18 joints @ 144wk
NCT01146652 · Phase 3 · combination
-15.9 joints @ 144wk
NCT01146652 · Phase 3 · monotherapy
-15.16 joints @ 168wk
NCT01146652 · Phase 3 · combination
-15.47 joints @ 168wk
NCT01146652 · Phase 3 · monotherapy
-15.26 joints @ 192wk
NCT01146652 · Phase 3 · combination
-15.01 joints @ 192wk
NCT01146652 · Phase 3 · monotherapy
-15.25 joints @ 216wk
NCT01146652 · Phase 3 · combination
-15.72 joints @ 216wk
NCT01146652 · Phase 3 · monotherapy
-15.43 joints @ 240wk
NCT01146652 · Phase 3 · combination
-15.59 joints @ 240wk
NCT01146652 · Phase 3 · monotherapy
-15.5 joints @ 264wk
NCT01146652 · Phase 3 · combination
-16.59 joints @ 264wk
NCT01146652 · Phase 3 · monotherapy
-14.67 joints @ 288wk
NCT01146652 · Phase 3 · combination
-18.65 joints @ 288wk
NCT01146652 · Phase 3 · monotherapy
-15.38 joints @ 312wk
NCT01146652 · Phase 3 · combination
-23.57 joints @ 312wk
NCT01146652 · Phase 3 · monotherapy
-15.51 joints @ 336wk
NCT01146652 · Phase 3 · combination
-15.96 joints @ 360wk
NCT01146652 · Phase 3 · combination
-16.42 joints @ 384wk
NCT01146652 · Phase 3 · combination
-16.3 joints @ 408wk
NCT01146652 · Phase 3 · combination
-16.62 joints @ 432wk
NCT01146652 · Phase 3 · combination
-15.64 joints @ 456wk
NCT01146652 · Phase 3 · combination
-15.43 joints @ 480wk
NCT01146652 · Phase 3 · combination
-16.21 joints @ 504wk
NCT01146652 · Phase 3 · combination
-13 joints @ 516wk
NCT01146652 · Phase 3 · combination
-3.9 joints @ 4wk
NCT03449758 · Phase 4 · registry result, not featured evidence
-4.1 joints @ 12wk
NCT03449758 · Phase 4 · registry result, not featured evidence
-4.7 joints @ 24wk
NCT03449758 · Phase 4 · registry result, not featured evidence
Physician Global VAS -40.51 mm @ 0wk
absolute change · mm
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 35 more results
-46.38 mm @ 0wk
NCT01146652 · Phase 3 · monotherapy
-43.98 mm @ 4wk
NCT01146652 · Phase 3 · combination
-47.94 mm @ 4wk
NCT01146652 · Phase 3 · monotherapy
-45.79 mm @ 8wk
NCT01146652 · Phase 3 · combination
-49.27 mm @ 8wk
NCT01146652 · Phase 3 · monotherapy
-47.02 mm @ 12wk
NCT01146652 · Phase 3 · combination
-50.2 mm @ 12wk
NCT01146652 · Phase 3 · monotherapy
-48.39 mm @ 24wk
NCT01146652 · Phase 3 · combination
-50.82 mm @ 24wk
NCT01146652 · Phase 3 · monotherapy
-48.94 mm @ 36wk
NCT01146652 · Phase 3 · combination
-51.12 mm @ 36wk
NCT01146652 · Phase 3 · monotherapy
-49.36 mm @ 48wk
NCT01146652 · Phase 3 · combination
-50.58 mm @ 48wk
NCT01146652 · Phase 3 · monotherapy
-49.98 mm @ 60wk
NCT01146652 · Phase 3 · combination
-51.4 mm @ 60wk
NCT01146652 · Phase 3 · monotherapy
-49.91 mm @ 72wk
NCT01146652 · Phase 3 · combination
-52.9 mm @ 72wk
NCT01146652 · Phase 3 · monotherapy
-50.28 mm @ 84wk
NCT01146652 · Phase 3 · combination
-55.84 mm @ 84wk
NCT01146652 · Phase 3 · monotherapy
-50.73 mm @ 96wk
NCT01146652 · Phase 3 · combination
-54.14 mm @ 96wk
NCT01146652 · Phase 3 · monotherapy
-50.43 mm @ 120wk
NCT01146652 · Phase 3 · combination
-54.33 mm @ 120wk
NCT01146652 · Phase 3 · monotherapy
-50.84 mm @ 144wk
NCT01146652 · Phase 3 · combination
-55.73 mm @ 144wk
NCT01146652 · Phase 3 · monotherapy
-50.49 mm @ 168wk
NCT01146652 · Phase 3 · combination
-53.21 mm @ 168wk
NCT01146652 · Phase 3 · monotherapy
-50.32 mm @ 192wk
NCT01146652 · Phase 3 · combination
-52.22 mm @ 192wk
NCT01146652 · Phase 3 · monotherapy
-51.49 mm @ 216wk
NCT01146652 · Phase 3 · combination
-54.67 mm @ 216wk
NCT01146652 · Phase 3 · monotherapy
-51 mm @ 240wk
NCT01146652 · Phase 3 · combination
-55.16 mm @ 240wk
NCT01146652 · Phase 3 · monotherapy
-51.18 mm @ 264wk
NCT01146652 · Phase 3 · combination
-55.27 mm @ 264wk
NCT01146652 · Phase 3 · monotherapy

+ 46 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levilimab's landscape · Sarilumab's landscape